8.700USD-9.47%Mkt Cap: 35.26M USDP/E: —Last update: 2026-05-26
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap35.26M USD
Enterprise Value66.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.28M USD
Revenue/Share—
Last Price8.700 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.14
EV/Revenue—
P/S—
P/B-2.73
EPS (TTM)-6.44
EPS (Forward)—
52W Range
4.1356% of range75.50
52W High75.50 USD
52W Low4.135 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE319.08%
ROA-599.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.33M USD
CapEx (TTM)64.44K USD
FCF Margin—
FCF Yield-8.99%
Net Debt8.78M USD
Net Debt/EBITDA-0.42
Balance Sheet
Debt/Equity-0.91
Current Ratio0.29
Quick Ratio0.12
Book Value/Sh-4.2370 USD
Cash/Share0.1650 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMar 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.19M
Float1.08M
Insiders74.41%
Institutions3.62%
Short Interest
Short Ratio4.6d
Short % Float7.07%
Short % Out.2.55%
Shares Short106.92K
Short (prev mo.)111.86K
Technical
SMA 506.577 (+32.3%)
SMA 20021.94 (-60.4%)
Beta0.10
S&P 52W Chg28.31%
Avg Vol (30d)25.90K
Avg Vol (10d)38.17K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—